– CANADA, Mississauga – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with growing revenues and a diverse portfolio of topical and immunology products, today announced the appointment of Samira Sakhia to its Board of Directors. Ms. Sakhia was most recently the Chief Financial Officer of Canada’s premier specialty pharmaceutical company, Paladin Labs Inc. (Paladin), for 14 years. As a senior member of the Paladin management team, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. During her tenure, Paladin achieved remarkable growth, increasing in value from $75.0 million to over $3.0 billion in 2014 when it was acquired by Endo International plc. Ms. Sakhia holds a Bachelor of Commerce degree in Finance and Accounting and a Masters of Business Administration in Strategy and Marketing from McGill University and is a Chartered Professional Accountant.
“We are thrilled to have Ms. Sakhia join our board,” said John London, Nuvo’s President and Co-CEO. “She has a wealth of pharmaceutical industry knowledge and experience that will serve Nuvo well as we focus on maximizing the revenue, profitability and value of the specialty pharma segment of our business through internal growth and acquisitions.”
About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group currently has four commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and multiple drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products and an immune system modulation platform that supports the development of drug products that modulate chronic inflammation processes resulting in a therapeutic benefit.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
